NovoCure Shares Are Trading Higher After the Company Announced FDA Approval of Optune Lua for the Treatment of Metastatic Non-small Cell Lung Cancer. Also, HC Wainwright & Co. Upgraded the Stock From Neutral to Buy and Raised Its Price Target From $24...

novocure股價上漲，公司宣佈FDA批准Optune Lua用於治療轉移性非小細胞肺癌。此外，HC Wainwright & Co. 將股票評級從中立上調至買入，並將目標股價從24美元提高至...

Benzinga · 10/16 19:39

NovoCure Shares Are Trading Higher After the Company Announced FDA Approval of Optune Lua for the Treatment of Metastatic Non-small Cell Lung Cancer. Also, HC Wainwright & Co. Upgraded the Stock From Neutral to Buy and Raised Its Price Target From $24 to $30.

novocure股價上漲，因公司宣佈FDA批准Optune Lua用於治療轉移性非小基站-5g肺癌。此外，HC Wainwright & Co. 將股票評級從中立提升至買入，並將目標股價從24美元提高至30美元。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。